Overcoming drug resistance through extracellular vesicle-based drug delivery system in cancer treatment.

IF 4.6 Q1 ONCOLOGY 癌症耐药(英文) Pub Date : 2024-12-12 eCollection Date: 2024-01-01 DOI:10.20517/cdr.2024.107
Long Zheng, Ruibai Chang, Bingjing Liang, Yitong Wang, Yushan Zhu, Zijing Jia, Jindian Fan, Zhe Zhang, Bo Du, Dexin Kong
{"title":"Overcoming drug resistance through extracellular vesicle-based drug delivery system in cancer treatment.","authors":"Long Zheng, Ruibai Chang, Bingjing Liang, Yitong Wang, Yushan Zhu, Zijing Jia, Jindian Fan, Zhe Zhang, Bo Du, Dexin Kong","doi":"10.20517/cdr.2024.107","DOIUrl":null,"url":null,"abstract":"<p><p>Drug resistance is a major challenge in cancer therapy that often leads to treatment failure and disease relapse. Despite advancements in chemotherapeutic agents and targeted therapies, cancers often develop drug resistance, making these treatments ineffective. Extracellular vesicles (EVs) have gained attention for their potential applications in drug delivery because of their natural origin, biocompatibility, and ability to cross biological barriers. Using the unique properties of EVs could enhance drug accumulation at target sites, minimize systemic toxicity, and precisely target specific cells. Here, we discuss the characteristics and functionalization of EVs, the mechanisms of drug resistance, and the applications of engineered EVs to overcome drug resistance. This review provides a comprehensive overview of the advancements in EV-based drug delivery systems and their applications in overcoming cancer drug resistance. We highlight the potential of EV-based drug delivery systems to revolutionize cancer therapy and offer promising strategies for more effective treatment modalities.</p>","PeriodicalId":70759,"journal":{"name":"癌症耐药(英文)","volume":"7 ","pages":"50"},"PeriodicalIF":4.6000,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11724354/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"癌症耐药(英文)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.20517/cdr.2024.107","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Drug resistance is a major challenge in cancer therapy that often leads to treatment failure and disease relapse. Despite advancements in chemotherapeutic agents and targeted therapies, cancers often develop drug resistance, making these treatments ineffective. Extracellular vesicles (EVs) have gained attention for their potential applications in drug delivery because of their natural origin, biocompatibility, and ability to cross biological barriers. Using the unique properties of EVs could enhance drug accumulation at target sites, minimize systemic toxicity, and precisely target specific cells. Here, we discuss the characteristics and functionalization of EVs, the mechanisms of drug resistance, and the applications of engineered EVs to overcome drug resistance. This review provides a comprehensive overview of the advancements in EV-based drug delivery systems and their applications in overcoming cancer drug resistance. We highlight the potential of EV-based drug delivery systems to revolutionize cancer therapy and offer promising strategies for more effective treatment modalities.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
基于细胞外囊泡的给药系统在癌症治疗中克服耐药性。
耐药性是癌症治疗中的一大挑战,常常导致治疗失败和疾病复发。尽管化疗药物和靶向疗法取得了进步,但癌症往往会产生耐药性,使这些治疗失效。细胞外囊泡(EVs)因其天然来源、生物相容性和穿越生物屏障的能力,在药物递送方面的潜在应用备受关注。利用细胞外囊泡的独特特性,可以提高药物在目标部位的蓄积,最大限度地减少全身毒性,并精确地靶向特定细胞。在此,我们将讨论 EVs 的特性和功能化、耐药机制以及工程化 EVs 在克服耐药性方面的应用。本综述全面概述了基于 EV 的给药系统的进展及其在克服癌症耐药性方面的应用。我们强调了基于 EV 的给药系统彻底改变癌症治疗的潜力,并为更有效的治疗模式提供了前景广阔的策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.60
自引率
0.00%
发文量
0
期刊最新文献
Mechanisms of immunotherapy resistance in small cell lung cancer. Mitochondrial genome variability and metabolic alterations reveal new biomarkers of resistance in testicular germ cell tumors. Ovarian tumor microenvironment contributes to tumor progression and chemoresistance. Role of the TME in immune checkpoint blockade resistance of non-small cell lung cancer. CIRCUS: CIRCUlating tumour cells in soft tissue Sarcoma - a short report.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1